Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Aspergillus clavatus NADH-cytochrome b5 reductase 2 (mcr1), partial CSB-YP006319AVC1
CSB-EP006319AVC1
CSB-BP006319AVC1
CSB-MP006319AVC1
CSB-EP006319AVC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus mRNA cap guanine-N7 methyltransferase (abd1), partial CSB-YP019902AVC
CSB-EP019902AVC
CSB-BP019902AVC
CSB-MP019902AVC
CSB-EP019902AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Ubiquitin-like protein ATG12 (atg12) CSB-YP002283AVC
CSB-EP002283AVC
CSB-BP002283AVC
CSB-MP002283AVC
CSB-EP002283AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Conserved oligomeric Golgi complex subunit 6 (cog6), partial CSB-YP005710AVC
CSB-EP005710AVC
CSB-BP005710AVC
CSB-MP005710AVC
CSB-EP005710AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri H/ACA ribonucleoprotein complex subunit 1 (gar1) CSB-YP009257NEZ
CSB-EP009257NEZ
CSB-BP009257NEZ
CSB-MP009257NEZ
CSB-EP009257NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Pescadillo homolog (nop7), partial CSB-YP017791NEZ
CSB-EP017791NEZ
CSB-BP017791NEZ
CSB-MP017791NEZ
CSB-EP017791NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Nucleolar protein 16 (nop16) CSB-YP015937NEZ
CSB-EP015937NEZ
CSB-BP015937NEZ
CSB-MP015937NEZ
CSB-EP015937NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Structure-specific endonuclease subunit slx4 (slx4), partial CSB-YP002843NEZ
CSB-EP002843NEZ
CSB-BP002843NEZ
CSB-MP002843NEZ
CSB-EP002843NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Histone H2A.Z (htz1) CSB-YP010100NEZ
CSB-EP010100NEZ
CSB-BP010100NEZ
CSB-MP010100NEZ
CSB-EP010100NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Eukaryotic translation initiation factor 3 subunit H (NFIA_015650) CSB-YP007537NEZ
CSB-EP007537NEZ
CSB-BP007537NEZ
CSB-MP007537NEZ
CSB-EP007537NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri NADH-cytochrome b5 reductase 2 (mcr1), partial CSB-YP006319NEZ1
CSB-EP006319NEZ1
CSB-BP006319NEZ1
CSB-MP006319NEZ1
CSB-EP006319NEZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Eukaryotic translation initiation factor 3 subunit B (prt1), partial CSB-YP007530NEZ
CSB-EP007530NEZ
CSB-BP007530NEZ
CSB-MP007530NEZ
CSB-EP007530NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Nucleolar protein 58 (nop58), partial CSB-YP015940NEZ
CSB-EP015940NEZ
CSB-BP015940NEZ
CSB-MP015940NEZ
CSB-EP015940NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Flap endonuclease 1 (fen1) CSB-YP008585NEZ
CSB-EP008585NEZ
CSB-BP008585NEZ
CSB-MP008585NEZ
CSB-EP008585NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Cytoplasmic tRNA 2-thiolation protein 2 (ncs2) CSB-YP003313NEZ
CSB-EP003313NEZ
CSB-BP003313NEZ
CSB-MP003313NEZ
CSB-EP003313NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Exportin-T (los1), partial CSB-YP026226NEZ
CSB-EP026226NEZ
CSB-BP026226NEZ
CSB-MP026226NEZ
CSB-EP026226NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Mediator of RNA polymerase II transcription subunit 14 (rgr1), partial CSB-YP013647NEZ
CSB-EP013647NEZ
CSB-BP013647NEZ
CSB-MP013647NEZ
CSB-EP013647NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Eukaryotic translation initiation factor 3 subunit G (TIF35) CSB-YP007536NEZ
CSB-EP007536NEZ
CSB-BP007536NEZ
CSB-MP007536NEZ
CSB-EP007536NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Vacuolar ATPase assembly integral membrane protein VMA21 (vma21), partial CSB-YP025866NEZ1
CSB-EP025866NEZ1
CSB-BP025866NEZ1
CSB-MP025866NEZ1
CSB-EP025866NEZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neosartorya fischeri Molybdopterin synthase catalytic subunit (mocs2) CSB-YP014706NEZ
CSB-EP014706NEZ
CSB-BP014706NEZ
CSB-MP014706NEZ
CSB-EP014706NEZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>